News & Updates

In the phase II TITAN-TCC* trial presented at ASCO GU 2022, the addition of ipilimumab to nivolumab led to improved responses in patients with pretreated (second/third line) advanced/metastatic or surgically unresectable transitional cell carcinoma (TCC).

Combining pembrolizumab with best supportive care (BSC) improved survival and response when used as second-line therapy in Asians with advanced hepatocellular carcinoma (HCC).

In individuals with advanced urothelial carcinoma (UC), a first-line maintenance treatment regimen comprising a combination of avelumab and best supportive care (BSC) provided better survival benefit than BSC alone, according to long-term and subgroup analyses of the phase III JAVELIN Bladder 100 trial presented at ASCO GU 2022.

The addition of tremelimumab to durvalumab (STRIDE regimen) in the first-line setting improved overall survival (OS) compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma (HCC), according to results of the phase III HIMALAYA trial.

Sarcoidosis patients with biopsy-verified non-necrotizing granulomatous inflammation are at greater risk of haematologic cancers and nonmelanoma skin cancer (NMSC) in the long term than the general population, a study has found.

In the phase II/III RELATIVITY-047 trial evaluating dual checkpoint inhibition for advanced melanoma, a new fixed-dose combination comprising the LAG-3 inhibitor relatlimab and the PD-1 inhibitor nivolumab fared better than nivolumab monotherapy.

The selective oral PARP1/2 inhibitor pamiparib is well tolerated and demonstrates favourable antitumour activity with durable responses in the treatment of patients with platinum-sensitive ovarian cancer or platinum-resistant ovarian cancer harbouring the germline BRCA mutation, according to the results of a phase II trial.

Pretreatment with the cyclin-dependent kinase 4/6 inhibitor trilaciclib appears to enhance the antitumour efficacy of gemcitabine plus carboplatin, with significant survival gains for patients with metastatic triple-negative breast cancer (mTNBC), according to the results of a phase II trial.